达格列净辅助沙库巴曲缬沙坦对冠心病介入治疗患者的疗效影响  

Effect of daglipzin assisted with sacubitril valsartan on patients with coronary heart disease after interventional therapy

作　　者：许鹏 张鸥[2] 曾显峰[2] Xu Peng;Zhang Ou;Zeng Xian-feng(Department of Critical Care Medicine,The Second People's Hospital of Zhenping,Zhenping 474250,Henan,China;Department of Cardiac Care,The First Affiliated Hospital of Nanyang Medical College,Nanyang 473000,Henan,China)

机构地区：[1]镇平县第二人民医院重症医学科,河南镇平474250 [2]南阳医学高等专科学校第一附属医院心内监护室,河南南阳473000

出　　处：《四川生理科学杂志》2024年第4期782-784,881,共4页Sichuan Journal of Physiological Sciences

摘　　要：目的:分析达格列净辅助沙库巴曲缬沙坦对冠心病介入治疗(Percutaneous coronary intervention,PCI)患者心功能、血清炎症因子水平的影响。方法:随机将镇平县第二人民医院2022年2月至2023年2月收治的PCI治疗患者150例分为研究组(75例)、对照组(75例)。对照组行沙库巴曲缬沙坦治疗,研究组采用达格列净辅助沙库巴曲缬沙坦方案治疗。治疗3 m比较两组疗效、心血管不良事件(Major adverse cardiac events,MACE)发生率,采用治疗前后每搏输出量(Stroke volume,SV)、左室射血分数(LVEF)、心输出量(Cardiac output,CO)评价患者心功能,采用一氧化氮(Nitricoxide,NO)、血管内皮生长因子(Vascular endothelial growth factor,VEGF)、内皮素(Endothelin-1,ET-1)及同型半胱氨酸(Homocysteine,Hcy)、C反应蛋白(C-reactive protein,CRP)、白细胞介素-6(Interleukin-6,IL-6)、肿瘤坏死因子(Tumor necrosis factor-α,TNF-α)水平评价患者血管内皮功能和炎性状态。结果:研究组总有效率94.67%高于对照组81.33%,治疗后研究组SV、LVEF、CO均高于对照组(P<0.05);治疗后研究组ET-1低于对照组,NO、VEGF、Hcy、TNF-α、CRP、IL-6高于对照组(P<0.05);治疗后研究组MACE发生率4.00%低于对照组14.67%(P<0.05)。结论:达格列净辅助沙库巴曲缬沙坦对PCI术后恢复治疗效果明显,利于患者心功能改善,可减少机体炎症反应及MACE事件发生。Objective:To analyze the effects of daglizin assisted by sacubitril valsartan on cardiac function and serum inflammatory factors in patients with percutaneous coronary intervention(PCI).Methods:A total of 150 PCI patients admitted to Zhenping Second People's Hospital from February 2022 to February 2023 were randomly divided into study group(75 cases)and control group(75 cases).The control group was treated with sacubitril valsartan,and the study group was treated with dagliprazin assisted sacubitril valsartan.After 3 months of treatment,the efficacy and incidence of major adverse cardiac events(MACE)were compared between the two groups.stroke volume(SV),left ventricular ejection fraction(LVEF)and cardiac output(CO)were used to evaluate the cardiac function of patients before and after treatment.Stroke volume(SV),left ventricular ejection fraction(LVEF)and cardiac output(CO)were used to evaluate the cardiac function of patients before and after treatment.The levels of Nitricoxide(NO),vascular endothelial growth factor(VEGF),Endothelin1(ET-1)and homocysteine(Hcy),C-reactive protein(CRP),interleukin-6(IL-6),Tumor necrosis factor-α(TNF-α)were used to evaluate the vascular endothelial function and inflammatory status of patients.Results:The total effective rate of the study group was 94.67%higher than that of the control group 81.33%.After treatment,the SV,LVEF and CO of the study group were higher than those of the control group(P<0.05).After treatment,ET-1 of the study group was lower than that of the control group,and NO,VEGF,Hcy,TNF-α,CRP and IL-6 were higher than that of the control group(P<0.05).After treatment,the incidence of MACE in the study group was 4.00%lower than that in the control group 14.67%(P<0.05).Conclusion:Daglipzin assisted with sacubitril valsartan has obvious effect on recovery after PCI,which is beneficial to the improvement of patients'cardiac function,and can reduce the inflammatory response and MACE events.

关 键 词：沙库巴曲缬沙坦 达格列净 冠心病 

分 类 号：R541.4[医药卫生—心血管疾病]